$1.64
+0.01 (+0.61%)
Open$1.63
Previous Close$1.63
Day High$1.68
Day Low$1.59
52W High$5.55
52W Low$1.03
Volume—
Avg Volume818.5K
Market Cap198.51M
P/E Ratio—
EPS$-1.28
SectorBiotechnology
Analyst Ratings
Strong Buy
16 analysts
Price Target
+2,661.6% upside
Current
$1.64
$1.64
Target
$45.29
$45.29
$33.37
$45.29 avg
$67.77
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 24.46M | 59.72M | 61.79M |
| Net Income | -140,524,510 | -17,457,928 | -16,293,891 |
| Profit Margin | -574.6% | -29.2% | -26.4% |
| EBITDA | -145,284,335 | -19,228,267 | -21,164,861 |
| Free Cash Flow | — | -18,637,383 | -17,592,445 |
| Rev Growth | — | -4.4% | +5.4% |
| Debt/Equity | 0.00 | 0.30 | 0.31 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |